A liver signalling pathway that protects metabolism but fuels tumours is the subject of a review published in Genes & Diseases.
Researchers at Tongji Hospital, Huazhong University of Science and Technology, mapped how FGF19–FGFR4 signalling acts as both guardian and destroyer.
The same liver signal can heal one disease and drive another. That is the verdict of a review examining FGF19–FGFR4 signalling.
The review, authored by Zhangfan Wu, Yijun Wang, Jiaqian Zhang, Siwen Li, Junjie Wen, Dian Hu, Junqing Jiang, Zerui Zhang, Xiangyuan Luo, and Limin Xia, appeared in the journal’s Volume 13, Issue 6, 2026. Its title poses the question directly: guardian or destroyer. The answer, the authors find, depends on disease stage, tissue context, and crosstalk with other pathways.
FGF19 Regulates Bile Acid Production
FGF19 is made in the intestine and travels to the liver, where it binds the receptor FGFR4 with help from the co-receptor β-Klotho. The interaction governs bile acid production, fat metabolism and glucose handling — processes the liver cannot do without. Bile acids aid digestion.

But when bile acids accumulate in excess they damage hepatic tissue, so FGF19 functions as a brake in a negative feedback loop. The review also traces the pathway’s role in liver regeneration and its behaviour in metabolic dysfunction-associated steatotic liver disease, alcohol-related liver disease, and conditions involving impaired bile flow. Those protective properties have drawn interest in therapies that mimic FGF19.
Copying the Signal Carries Risks
Safety remains the sticking point for FGF19 mimics. The authors examine clinical trials of aldafermin, an engineered FGF19 analogue, which has shown reductions in liver fat alongside improvements in select measures of liver disease and fibrosis. Reports of diarrhoea, plus observations of potential cancer-promoting effects in certain animal models, underline why the review calls for thorough safety assessment of any pathway mimic.
Cancer Care Aimed to Block the Same Signal
In hepatocellular carcinoma, the most common primary liver cancer, the picture reverses. Excessive FGF19–FGFR4 activity can support tumour cell survival, spread, immune suppression and resistance to treatment. Oncology research therefore aims to shut the pathway down rather than boost it.
One targeted strategy is selective FGFR4 inhibition. In an early clinical trial summarized in the review, the inhibitor fisogatinib achieved an objective response rate of 17 percent in patients with FGF19-positive tumours, compared with no responses in the FGF19-negative group. The authors argue this supports testing tumour FGF19 expression as a predictive biomarker to identify patients likely to benefit from receptor blockade.
Combination approaches — pairing FGFR4 inhibitors with immunotherapy or other anticancer agents — show promise in experimental studies, though clinical evidence remains limited, the review states. Acquired FGFR4 mutations can drive drug resistance, reinforcing the need for better inhibitors and treatment selection.
The central challenge the authors leave open: separating the pathway’s metabolic benefits from the signals that stimulate unwanted cell growth, so the same circuit can be harnessed in one disease and silenced in the other. How to keep the brake on bile acids while cutting the tumour’s fuel supply is not yet solved.